CD19 and acute lymphoblastic leukemia: To validate miR-532-5p and miR-103a-3p as reliable references in BCP ALL studies, we additionally analyzed 13 PDX ALL samples with viability exceeding 25% based on FSC/SSC and over 60% positivity for human CD19.